Trial Profile
A Phase I Study to Determine the Safety and Pharmacokinetics of Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Crisantaspase (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 01 Jun 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jun 2017.
- 01 Jun 2017 Status changed from recruiting to withdrawn prior to enrolment.
- 05 Jan 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.